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Perspectives on blockade of TGFβ 
overexpression
Y Huang1, WA Border1 and NA Noble1
Many approaches to blocking profibrotic TGFβ overexpression are 
under way. Therapeutic targeting of TGFβ–Smad signaling holds 
promise for slowing or halting progressive renal disease. In this issue, 
Fukasawa et al., using the unilateral ureteral obstruction model, 
provide a new target for therapeutic intervention by identifying loss of 
the Smad corepressors Ski and SnoN as a mechanism that amplifies the 
profibrotic actions of TGFβ.
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Progressive kidney disease is character-
ized by accumulation of extracellular 
matrix (ECM) in glomeruli and tubu-
lointerstitium leading to loss of kidney 
function and kidney failure regardless 
of the underlying disorder. Slowing 
or stopping this ECM build-up is the 
biggest challenge facing nephrologists 
today. Th us a major eff ort has been the 
analysis of mechanisms involved in the 
pathogenesis of chronic renal fi brosis. 
Th rough understanding of these mech-
anisms, it might be possible to prevent 
the development of progressive renal 
insuffi  ciency, thus minimizing the clini-
cal, social, and economic impact of end-
stage renal disease.
Th e studies of Brenner and colleagues 
(reviewed by Neuringer and Brenner1) 
were an early systematic analysis of fac-
tors that underlie the progression of renal 
disease. Th ese studies demonstrated that 
hyperfiltration and increased intra-
glomerular pressure caused a progressive 
decrease of glomerular fi ltration, resulting 
in complete organ failure. Th en, in 1990, 
three papers by Border et al. (reviewed by 
Border and Noble2) suggested that TGFβ 
overexpression was a key mediator of 
fi brotic renal disease. As shown in Figure 
1, this area of research has grown expo-
nentially, so that now therapeutic target-
ing of TGFβ overexpression holds much 
hope for slowing or halting pathologi-
cal ECM accumulation. Th e profi brotic 
actions of TGFβ include stimulation of 
ECM synthesis, inhibition of ECM degra-
dation, and modulation of ECM receptor 
expression to facilitate cell–ECM inter-
action. Over a period of years, TGFβ 
overexpression has been shown to be a 
component of virtually every fi brotic dis-
ease in both humans and animal models. 
Additional basic research uncovered the 
existence of TGFβ isoforms and identi-
fi ed mechanisms of TGFβ activation and 
TGFβ signaling at the level of extracel-
lular ligand activation and intracellular 
signal transduction. Th e identifi cation of 
the regulation and dysregulation of post-
receptor signaling shed new light on the 
pathways by which TGFβ contributes to 
fi brotic kidney disease, as Fukasawa et al.3 
show in this issue.
But fi rst, some background. TGFβ is 
synthesized as an inactive precursor con-
taining an amino-terminal prodomain. 
Th e prodomain, also termed latency-asso-
ciated protein, is cleaved within the Golgi 
apparatus but remains non-covalently 
bound to TGFβ, thereby preventing TGFβ 
from binding to its receptors. Th is latent 
complex of TGFβ and latency-associated 
protein also associates with latent TGFβ-
binding proteins before secretion from the 
cell. Aft er secretion, most TGFβ is stored 
in the ECM as part of this inactive com-
plex with latency-associated protein and 
latent TGFβ-binding proteins. Th e latent 
TGFβ complex can be activated into 
mature, biologically active TGFβ through 
the actions of proteases, such as plasmin, 
or by thrombospondin-1. Aft er release 
from the latent complex, TGFβ dimers 
initiate their cellular effects by bind-
ing to cell membrane receptors. Th ree 
TGFβ receptors are involved in TGFβ 
signal transduction. TGFβ first binds 
to the type III TGFβ receptor, which 
then presents the ligand to the type II 
receptor or directly binds to the type II 
receptor. Th e type I receptor subsequently 
is recruited to form a stable receptor com-
plex consisting of two receptors of each 
type, allowing phosphorylation of the 
glycine/serine-rich sequences by the type 
II receptor kinases. Th is phosphoryla-
tion activates the type I receptor kinases, 
resulting in autophosphorylation of the 
type I receptor and phosphorylation of 
certain members of the Smad family 
of signal-transducing proteins. Smad2 
and Smad3 phosphorylated by the type 
I receptor homodimerize and then bind 
to Smad4. Th e heteromeric complex of 
Smad2 or Smad3 and Smad4 translocates 
to the nucleus, where it regulates the tran-
scription of target genes.4
Smad4 therefore seems to be critical for 
the Smad signaling pathway. Studies have 
shown that defi ciency of Smad4 prevents 
TGFβ-induced collagen but not fi bronec-
tin expression, demonstrating that both 
Smad-dependent and Smad-independ-
ent signaling pathways mediate TGFβ-
induced ECM overexpression.5 With the 
use of mouse embryo fi broblasts isolated 
from either Smad3 or Smad2 knockout 
(KO) mice, TGFβ-induced collagen type 
I and type III expression was ablated 
in Smad3 KO fibroblasts, but not in 
Smad2 KO fi bro blasts.6 A 900-gene chip 
microarray analy sis further indicated 
that Smad3 is an essential mediator of 
TGFβ signaling.7
In db/db mice, a genetic model of 
type 2 diabetes, compared with control 
mice, increased nuclear localization of 
Smad3 in glomerular and tubular cells 
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and increased binding of nuclear pro-
teins to the Smad-binding element were 
seen.8 Similar increases in nuclear local-
ization of Smad3 and activation of the 
Smad-binding element were observed 
in kidneys of mice with streptozotocin-
induced (type 1) diabetes, and these 
increases were prevented by administra-
tion of TGFβ-neutralizing antibodies. 
When Smad3 KO mice were treated with 
streptozotocin, diabetes-induced thick-
ening of glomerular basement mem-
brane, albuminuria, and upregulation of 
fi bronectin and collagen IV expression 
were attenuated, which suggests that local 
activation of Smad3 is important in the 
development of diabetic nephropathy.9
In unilateral ureteral obstruction, 
upregulation of TGFβ is thought to 
induce epithelial–mesenchymal transi-
tion of renal tubules that then go on to 
deposit ECM. Aft er unilateral ureteral 
obstruction, Smad3 KO mice were pro-
tected from tubulointerstitial fibrosis, 
as evidenced by blocking of epithelial–
mesenchymal transition and decreased 
monocyte infl ux and collagen accumu-
lation. Primary cultures of renal tubular 
epithelial cells from Smad3 wild-type 
mice underwent epithelial–mesenchymal 
transition aft er TGFβ treatment, as evi-
denced by loss of E-cadherin expression, 
induction of α-smooth muscle cell actin 
expression, and induction of the expres-
sion of Snail (a potent repressor of tran-
scription of the E-cadherin gene), none 
of which occurred in cells prepared from 
Smad3 KO mice.10 Th ese results provide 
clear evidence that activation of Smad3 
mediates the profi brotic actions of TGFβ 
and is a critical feature of renal fi brosis. 
Three Smad transcriptional corepres-
sors, namely Ski (Sloan-Kettering Insti-
tute proto-oncogene), SnoN (Ski-related 
novel gene, non-Alu-containing), and 
TGIF (TG-interacting factor), have been 
identified.11 Once bound to corepres-
sors, activated Smads form transcrip-
tionally inactive complexes. Th e amount 
of transcriptional corepressor present 
within a cell in a given circumstance may 
determine the ultimate outcome of a 
TGFβ response.
In their new paper, Fukasawa et al.3 
demonstrate a dramatic reduction of 
the Smad transcriptional corepressors 
Ski and SnoN at the protein level in the 
fi brotic kidney aft er obstructive injury. 
Because SnoN and Ski function as Smad 
transcriptional antagonists, their loss 
represents elimination of a crucial nega-
tive control mechanism for TGFβ action, 
potentially leading to unrestrained TGFβ 
signal transduction in the kidney under 
pathological conditions. The authors 
also show that SnoN and Ski proteins are 
reduced not by decreases in their mRNA 
expression but by accelerated degradation  
involving the ubiquitin–proteasome path-
way. Th ese results strongly suggest that 
loss of Smad corepressors is an important 
mechanism that amplifies profibrotic 
TGFβ signaling in this model. It remains 
to be seen whether the downregulation 
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of Smad corepressors is involved in the 
progression of other forms of chronic 
renal disease.
In summary, the profi brotic actions of 
TGFβ have been extensively studied for 
the past 15 years. Work has progressed 
from showing TGFβ overexpression in 
fi brotic diseases to uncovering a complex 
system where profi brotic TGFβ signal-
ing may be dramatically amplifi ed in the 
diseased kidney. Th is may explain why it 
is so diffi  cult to completely block TGFβ 
signaling and halt the progression of 
chronic renal fi brosis. On the other hand, 
such a complex system also provides tar-
gets for intervention. Th e sheer number 
of available targets in this complex sys-
tem off ers hope that in the future it will 
be possible to prevent progressive renal 
disease by blocking the fi brotic eff ects of 
TGFβ overexpression.
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Figure 1 | Number of publications on TGF-β and the kidney since 1990 according to PubMed.
